Semaglutide, marketed as Ozempic and Wegovy (injectable forms) and Rybelsus (oral form), is a glucagon-like peptide-1 (GLP-1) receptor agonist used for managing type 2 diabetes and chronic weight management
In addition, AST treatment reduced clinical scores and ameliorated disease severity, further highlighting the protective potential of AST in the MS model
Newer options appear more potent.(20) Cardiovascular data Only certain GLP-1s have proven cardiovascular benefits for at-risk diabetics thus far
I still think it would be fascinating
Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa
On the other hand, Wegovy is available in dosage strengths of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg